大细胞神经内分泌癌的手术治疗结局:基于国家癌症数据库的分析
本研究利用美国国家癌症数据库(2004-2015)分析I-IIIA期大细胞神经内分泌癌(LCNEC)的手术结局,共纳入6092例患者。结果显示,I期和II期手术患者5年生存率分别为50%和45%,IIIA期和N2期分别为36%和32%;与立体定向放疗或放化疗相比,手术与生存获益相关。围手术期化疗与病理II-IIIA期生存改善相关。
要点
- I-IIIA期LCNEC患者中,手术与生存获益相关,优于立体定向放疗或放化疗。
- I期和II期手术患者5年生存率分别为50%和45%,IIIA期和N2期分别为36%和32%。
- 围手术期化疗与病理II-IIIA期LCNEC患者生存改善相关。
核心结论
- 对于医学上适合的早期和局部晚期LCNEC患者,应提供手术,并配合指南一致的诱导或辅助治疗。
研究设计与样本
- 基于美国国家癌症数据库(2004-2015)的回顾性队列研究,纳入6092例I-IIIA期LCNEC患者,按治疗方式分为根治性放化疗与手术组。
主要发现
- I、II、IIIA和cN2期患者接受手术的比例分别为96%、94%、75%和62%,至少85%的患者实现完全切除。
- I期和II期手术患者5年生存率分别为50%和45%,IIIA期和N2期分别为36%和32%。
- 与I期立体定向放疗及II-IIIA期放化疗相比,手术与生存获益相关。
- 手术患者按分期生存一般差于腺癌患者,但优于SCLC患者。
- 围手术期化疗与病理II-IIIA期患者生存改善相关。
临床怎么用
- 对医学上适合的I-IIIA期LCNEC患者,应考虑手术切除,并结合指南推荐的诱导或辅助化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There are limited small, single-institution observational studies examining the role of surgery in large cell neuroendocrine cancer (LCNEC). We investigated the outcomes of surgery for stage I to IIIA LCNEC by using the National Cancer Database. METHODS: Patients with stage I to IIIA LCNEC were identified in the National Cancer Database (2004-2015) and grouped by treatment: definitive chemoradiation versus surgery. Overall survival, by stage, was the primary outcome. Outcomes of surgical patients were also compared with those of patients with SCLC or other non-small cell histotypes. RESULTS: A total of 6092 patients met the criteria: 96%, 94%, 75%, and 62% of patients received an operation for stage I, II, IIIA, and cN2 disease, respectively. Complete resection was achieved in at least 85% of patients. The 5-year survival rates for patients undergoing an operation for stage I and II LCNEC were 50% and 45%, respectively. Surgical patients with stage IIIA and N2 disease had 36% and 32% 5-year survival rates, respectively. When compared with stereotactic body radiation in stage I disease and chemoradiation in patients with stage II to IIIA disease, surgery was associated with a survival benefit. Patients with LCNEC who underwent an operation generally experienced worse survival by stage than did those with adenocarcinoma but experienced improved survival compared with patients with SCLC. Perioperative chemotherapy was associated with improved survival for pathologic stage II to IIIA disease. CONCLUSIONS: Surgery is associated with reasonable outcomes for stage I to IIA LCNEC, although survival is generally worse than for adenocarcinoma. Surgery should be offered to medically fit patients with both early and locally advanced LCNEC, with guideline-concordant induction or adjuvant therapy.
引用
- Raman V, Jawitz OK, Yang CJ, et al. Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. J Thorac Oncol. 2019. PMID: 31557535. doi:10.1016/j.jtho.2019.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。